Acarix announce final outcome in oversubscribed rights issue
Malmö, Sweden September 11, 2020
Acarix announce final outcome in oversubscribed rights issue
Acarix AB ("Acarix" or the "Company") has completed the new share issue of a maximum of 86,156,738 shares with preferential rights for the Company's existing shareholders, which was resolved by the extra general meeting on 11 August 2020 (the "Rights Issue"). Acarix today announces the final outcome of the Rights Issue, which shows, in line with what was communicated 9 September 2020, that the Rights Issue has been oversubscribed.
The Rights Issue amounted to a maximum of approximately SEK 56 million before deduction of costs related to the Rights Issue. The final outcome shows that 70,916,535 shares, corresponding to approximately 82.3 percent of the Rights Issue, was subscribed by exercise of subscription rights and that 35,267,606 shares, corresponding to approximately 40.9 percent of the Rights Issue had been subscribed without use of subscription rights. Hence, the Rights Issue was in total subscribed to approximately 123.2 percent. Guarantee undertakings entered into in connection with the Rights Issue will not be utilized.
The board of directors has, in accordance with adopted principles for allotment, allotted 86,156,738 offered new shares in the Rights Issue. The Rights Issue provides the Company with approximately SEK 56 million before deduction of costs related to the Rights Issue.
" I would like to thank all investors who participated in the issue. It is gratifying to see the great interest in Acarix and our business. The capital provided now enables an acceleration in our continued work. " – Per Persson, CEO, Acarix AB
Notice of allotment
Those who have subscribed for shares without use of subscription rights will be allotted shares in accordance with the principles for allotment set out in the prospectus which has been prepared for purposes of the Rights Issue. Notice of potential allotment of shares subscribed for without use of subscription rights will be provided through the distribution of a settlement note. Payment shall be made no later than three (3) banking days following issuance of the settlement note. Those who have not been allotted shares will not receive any notification hereof. If payment is not made at the right time, the shares may be transferred to another party. Those who subscribe for shares without preferential rights through its nominee will receive notice of allotment in accordance with the nominee's procedures.
Number of shares, votes, share capital and dilution
Through the Rights Issue, Acarix share capital will increase by SEK 861,567.38 to SEK 1,378,507.81. The total number of shares and votes will increase by 86,156,738, from 51,694,043 to 137,850,781 shares and votes. For existing shareholders who did not subscribe for their pro rata share of the Rights Issue, a dilution of approximately 62.5 percent of the total number of shares and votes in the Company following the rights issue will arise. On or around seven days following the registration of the rights issue with the Swedish Companies Registration office, paid subscribed shares (BTA) will be converted into new shares without any specific notice from Euroclear Sweden. The new shares will be admitted to trading in connection with the BTAs conversion to shares, which is expected to take place around week 41, 2020.
Redeye AB is acting as financial adviser and Baker McKenzie is acting as legal adviser to Acarix in connection with the Rights Issue. Hagberg & Aneborn Fondkommission AB is acting as issuing agent.
The information in this press release has been published through the agency of the contact persons below at the time and date indicated by GlobeNewswire, the news distributor of Acarix AB, in conjunction with the publication of this press release. The persons below can also be contacted for further information.
Per Persson, VD Acarix AB,
+46 (0)73 600 59 90,
Christian Lindholm, CFO Acarix,
+46 (0)70 511 83 33,
Acarix was established in 2009 and is listed on Nasdaq First North Premier Growth Market (ticker: ACARIX). Acarix’s CADScor®System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen. Readout is obtained in less than 10 minutes. Safe and suitable for use in both out- and inpatient settings, the CADScor®System thus has the potential to play a major role in patient triage, avoiding the need for many patients to undergo stressful invasive diagnostic procedures. Wildeco Ekonomisk Information AB (+46 8 545 271 00, firstname.lastname@example.org) is Certified Adviser to Acarix. For more information please visit www.acarix.com.
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Acarix in any jurisdiction, neither from Acarix nor from someone else.
This press release is not a prospectus for the purposes the (EU) 2017/1129 Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction. A prospectus, corresponding to an EU Growth prospectus including published supplements, has been prepared by the Company and published on the Company's web page.
This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness. Redeye is acting for Acarix in connection with the Rights Issue and no one else and will not be responsible to anyone other than Acarix for providing the protections afforded to its clients nor for giving advice in relation to the Rights Issue or any other matter referred to herein.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zeeland, Singapore, South Africa, the United States or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.
In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.
This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's and the group's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the group operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is not required by law or Nasdaq First North Growth Market rule book for issuers.
Information to distributors
Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (“MiFID II”); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the “MiFID II Product Governance Requirements”), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any “manufacturer” (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares in Acarix have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the “Target Market Assessment”). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the shares in Acarix may decline and investors could lose all or part of their investment; the shares in Acarix offer no guaranteed income and no capital protection; and an investment in the shares in Acarix is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Rights Issue.
For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in Acarix.
Each distributor is responsible for undertaking its own target market assessment in respect of the shares in Acarix and determining appropriate distribution channels.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Key dates for the Yara International ASA 2019 dividend23.10.2020 17:33:48 CEST | Press release
Oslo, 23 October 2020: Reference is made to Yara’s stock exchange release dated 23 October 2020 regarding the Extraordinary General Meeting and additional dividend of NOK 18 per share. The following key dates will apply for the additional dividend: Ex dividend NOK 18.00 as of: 18 November 2020 Record date: 19 November 2020 Dividend payment date: 27 November 2020 ADR dividend payment date: 4 December 2020 Contact Thor Giæver, Investor Relations Cellular: (+47) 480 75 356 E-mail: email@example.com About Yara Yara grows knowledge to responsibly feed the world and protect the planet. Supporting our vision of a world without hunger, we pursue a strategy of sustainable value growth, promoting climate-friendly and high-yielding crop nutrition solutions for the world’s farming community and food industry. Yara’s ambition is to be the Crop Nutrition Company for the Future. We are committed to creating value for our customers, shareholders and society at large, as we work to develop a more su
Nøkkeldatoer for Yara International ASA tilleggsutbytte23.10.2020 17:33:48 CEST | Pressemelding
Oslo, 23. oktober 2020: Det vises til børsmelding 23. oktober 2020 om ekstraordinær generalforsamling og tilleggsutbytte på 18 kroner per aksje. Følgende nøkkeldatoer gjelder for tilleggsutbyttet: Aksjen handles eks. utbytte NOK 18,- fra: 18. november 2020 Eierregisterdato: 19. november 2020 Utbetalingsdato: 27. november 2020 Utbetalingsdato ADR: 4. desember 2020 Kontakt Thor Giæver, investorkontakt Mobil: (+47) 480 75 356 E-post: firstname.lastname@example.org Om Yara Yara bringer kunnskap om hvordan verdens befolkning kan mettes og kloden beskyttes. Bak vår visjon om en verden uten sult ligger en strategi som fremmer klimavennlige og ressurseffektive løsninger for landbruk og matvareindustri over hele verden. Vår ambisjon er å være fremtidens leverandør av plantenæring. Vi har forpliktet oss til å skape verdi for kunder, aksjonærer, og samfunnet rundt oss i arbeidet med å skape en mer bærekraftig matverdikjede. For å nå dette målet, har vi satt oss i førersetet for utviklingen av digitale verk
Kommuniké från extra bolagsstämma den 23 oktober 2020 i Saniona AB23.10.2020 17:15:00 CEST | Pressemelding
PRESSMEDDELANDE 23 oktober 2020 Idag, den 23 oktober 2020, hölls extra bolagsstämma i Saniona AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet. Beslut om (A) personaloptionsprogram; och (B) riktad emission av teckningsoptioner samt godkännande av överlåtelse av teckningsoptioner Stämman beslutade, i enlighet med styrelsens förslag, om införande av ett optionsprogram för samtliga av bolagets anställda, inklusive bolagets verkställande direktör, ledningsgrupp (exklusive CSO Jørgen Drejer), Vice Presidents och samtliga övriga anställda. Personaloptionerna omfattar samtliga av bolagets nuvarande anställda (inklusive nyligen anställda och personer som kommer att anställas under perioden fram till nästa årsstämma). Stämman beslutade även om riktad emission av teckningsoptioner samt godkännande av överlåtelse av teckningsoptioner. Programmet innebär att högst 7 976 690 personaloptioner ska erbjudas deltagarna. Optionsinnehavarna
Bulletin from the extraordinary general meeting on October 23, 2020 in Saniona AB23.10.2020 17:15:00 CEST | Press release
PRESS RELEASE October 23, 2020 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Today, on October 23, 2020, an extraordinary general meeting was held in Saniona AB. A summary of the resolutions adopted follows below. All resolutions were adopted with the required majority of votes. Resolution on (A) employee option program; and (B) directed issue of warrants and approval of transfer of warrants The meeting resolved, in accordance with the proposal from the board of directors, to adopt an option program for all company employees, including the company’s CEO, the executive team (excluding the CSO Jørgen Drejer), vice presidents and all other employees. The employee options will cover all current employees, including the employees that have recently been hired, as well as the employees that will be hired up until the next annual general meeting (AGM). The meeting also resolved
PRF: Subsidiary of AS PRFoods is borrowing from the Rural Development Foundation23.10.2020 17:00:00 CEST | Press release
AS PRFoods has approved the borrowing of the six-year investment loan in the amount of one million euros from the Rural Development Foundation by its subsidiary Osaühing Vettel under the measure „COVID-19 loan to bio- and rural enterprises” (aid measure 3.3). The interest rate of the loan will be 2.5% for the first two years and 4.5% thereafter. The investment loan shall be used for automatization of the factory of Osaühing Vettel in Saaremaa. The loan is secured by a mortage and a commercial pledge on the assets of Osaühing Vettel to the following rankings of existing creditors and a 100% guarantee from AS PRFoods. Indrek Kasela AS PRFoods Mermber of the Management Board T: +372 452 1470 email@example.com www.prfoods.ee
Notice of Yara Extraordinary General Meeting23.10.2020 16:30:00 CEST | Press release
Oslo, 23 October 2020: Yara International ASA will hold an Extraordinary General Meeting on Tuesday 17 November at 17:00 CET to approve the Board’s proposal to pay an additional dividend of NOK 18 per share. The meeting notice is available on the company’s website. In accordance with Norwegian temporary legislation exempting companies from physical meeting requirements to reduce Covid-19 risk, the Extraordinary General Meeting will be held as a digital meeting only, with no physical attendance for shareholders. The complete notice of the Annual General Meeting will be distributed to Yara’s registered shareholders and is also available on Yara’s website: https://www.yara.com/investor-relations/reports-and-presentations-2020/ Contact Thor Giæver, Investor Relations Cellular: (+47) 480 75 356 E-mail: firstname.lastname@example.org About Yara Yara grows knowledge to responsibly feed the world and protect the planet. Supporting our vision of a world without hunger, we pursue a strategy of sustainable